Remove Dosage Remove Drug Development Remove Vaccines
article thumbnail

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

PharmaTech

s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. Kennedy Jr.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

CMS is issuing unique J-codes for 505(b)(2) drugs, classifying them as sole-source products if not therapeutically equivalent. This pathway reduces submission denial risk, accelerates drug development, and offers potential market exclusivity for up to 7 years.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How AI Brings Pharmacogenetics to the Frontline of Precision Medicine

Pharmacy Times

By incorporating a patient's genetic profile into therapeutic decision-making, pharmacists can identify optimal drug choices and dosages while minimizing the risk of adverse events (AEs). This is particularly vital in polypharmacy scenarios, where the risk of drug-drug interactions and cumulative toxicity is high.

article thumbnail

Achieving Targeted Delivery with Nanoscale Systems

PharmaTech

In addition, stability during storage can be an issue for some nanoscale systems, requiring careful formulation development. All these challenges tend to lead to high costs for therapeutics and vaccines leveraging nanoscale drug delivery systems. References 1. Tenchov, R.

Dosage 52
article thumbnail

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Pharmacy Times

SHOW MORE With robust pipelines, cell therapy remains the major driver for drug development. The field is expanding into autoimmune diseases, with nononcology trials representing 51% of the pipeline by late 2024. Trends Pharmacol Sci. 2024;45(5):406-418. doi:10.1016/j.tips.2024.03.004

article thumbnail

MilliporeSigma and Simtra Launch Five-Year Agreement for Drug Substance, Drug Manufacturing Services

PharmaTech

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines Feliza Mirasol April 30th 2024 Podcast In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Dosage 52
article thumbnail

FDA approves label updates for BMS’ CAR T cell therapies

Pharmaceutical Technology

Last month, European Commission approved the new subcutaneous (SC) formulation of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) with a dosage strength of 600 mg/vial, expanding treatment options for various adult solid tumours. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.